RCT | Ticagrelor is ineffective for reducing vaso-occlusive crises in pediatric sickle cell disease. 25 Jul, 2022 | 12:50h | UTC Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study – Blood
Open access
Open access